Home › Amyloidosis › Maryland
Amyloidosis clinical trials in Maryland
7 studies for Amyloidosis are looking for participants at sites in Maryland.
Cities in Maryland
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
- Research Site, Baltimore
RecruitingObservational study
Ages 18 to 130 · All sexes · Updated Sep 23, 2026 · NCT06465810TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
- Clinical Trial Site, Baltimore
RecruitingPhase 3
Ages 18 to 85 · All sexes · Updated Sep 16, 2026 · NCT07052903TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
- Clinical Trial Site, Baltimore
RecruitingPhase 3
Ages 18 to 85 · All sexes · Updated Sep 15, 2026 · NCT07223203ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
- Clinical Trial Site, Baltimore
RecruitingObservational study
All ages · All sexes · Updated Sep 8, 2026 · NCT04561518Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
- University of Maryland Medical Center, Baltimore
- Johns Hopkins University, Baltimore
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Aug 4, 2026 · NCT06563895Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated May 19, 2026 · NCT06974877MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
- Johns Hopkins University, Baltimore
RecruitingPhase 3
Ages 18 to 90 · All sexes · Updated Mar 27, 2026 · NCT06128629From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.